and gender to gain more insight into tailored risk prediction and communication of risk to general practitioners (GPs) and/or participants. Methods: In this retrospective study, data was used of 57,421 participants who underwent a colonoscopy after a positive FIT in the Flemish CRC screening programme between October 2013 until July 2016. Analyses were performed with multinomial logistic regression to predict the probability of normal or noncancerous lesions, precancerous lesions, in situ or invasive cancers. Additionally, odds ratios (OR) were established to visualize the magnitude of the differences between risk profiles within a population with positive FIT, based upon a combination of the quantitative FIT, age and gender. Results: The amount of false positive FIT results followed up by colonoscopy is $27%, where $20% are not followed up at all by colonoscopy within 6 months after a positive FIT. Based on our risk profile calculation, we found a significant difference between the risk of having a normal outcome, a precancerous lesion, an in situ or an invasive cancer. For example, the detection of invasive cancer was 58 (OR) times more likely in a male of 74 years old with a FIT result of ! 1,000 ng/ml compared to a woman of 56 years old with a FIT result of 75 ng/ml. Conclusion: The differences in precancerous lesions or CRC according to our calculated risk profiles, justifies an approach where participants with a positive FIT are not all treated in the same way, based on a binary FIT. Participants and/or their GPs should be informed about individual risks. This will promote informed decision to an extent where participants and/or professionals can make decisions on follow-up. How to communicate this personalised information to participants needs to be discussed and tested. Contrary to the participant, professionals such as GPs should be provided with extra insight in the risk differences per patient, which supports their clinical decision making. The approach above could be extended by adding simple risk factors such as BMI, diet, alcohol intake, family history etc., creating the opportunity to more accurately discriminate between participants with a normal outcome, precancerous lesion, in situ or invasive cancer. Colonoscopy follow up based upon the quantitative FIT, combined with age, gender and additional risk factors instead of upon a binary FIT result only, will probably increase accuracy.

Conclusion: Thermal ablation is an effective treatment for colorectal cancer pulmonary metastases. We found no difference in outcome according to the type of thermal ablation used. Small pneumothoraces were common with both types of thermal ablation, but otherwise, both techniques were well-tolerated.Legal entity responsible for the study: The authors.

No abstract

Tyrosine kinase inhibitors (TKIs) have become a prominent option in the therapeutic arsenal of several cancers. The safety of these drugs has shown various toxicities with varying frequency and severity between different agents. The aim of this study is to describe the safety profile of different classes of TKI used in various solid tumors. It is a retrospectively descriptive study conducted in the Department of Medical Oncology at Hassan II University Hospital of Fez, Morocco, over a period of 6 years from April 2013 until April 2019. It included 216 patients who received one or more TKI for different indications in solid tumors. The average age in our series was 61.4 years with a sex ratio F/M of 1.07. Among the most used TKIs in our department according to their availability: Imatinib (32%) and sunitinib (32%). All patients received one or more tyrosine kinase inhibitors according to the indication. Kidney cancer was the most common malignancy (36%), followed by gastrointestinal stromal tumors (33%). The median duration of treatment was 15 months with extremes of 1 month and 102 months. The main side effects were: Cutaneous in 43% of patients. Digestive toxicity occurred in 36% of cases. Hematotoxicity was reported in 33% of cases. The safety profile of TKIs used in our study was comparable to their global tolerance reported in literature. More studies are needed to investigate the relationship between their toxicity and their efficacy in Moroccan population.

Background: Inflammatory lung pseudotumors are extremely rare. Their pathogenesis is controversial, their diagnosis is often difficult, and their clinical behavior can be unpredictable.Case présentation: This is a 48-year-old patient hospitalized for management of an intracranial hypertension syndrome whose radiological assessment was in favor of metastatic brain lesion with primary pulmonary origin, the biopsy with anatomopathological study posed the diagnosis of '' an inflammatory myelofibroblastic tumor associated with a TGF-ROS 1 fusion ALK-negative, the patient benefited from treatment with a targeted therapy based on crizotinib with good clinical response, in particular the regression of symptoms and radiological response, patient currently still under treatment. Conclusion:Immunohistochemistry for ROS1 helped to support the diagnosis of a subset of ALK negative inflammatory myofibroblastic tumors.